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Purpose: Clear cell sarcoma (CCS) is a rare high-grade malignant tumor accounting for less than 1% of all soft
tissue sarcomas. CCS in the spine is much rarer and poorly understood. The objective of our study is to discuss
clinical characteristics, surgical management and outcomes of spinal CCS.
Methods: Between October 2011 and December 2014, ﬁve patients with spinal CCS underwent surgical
treatment in our center. Five cases from literature focusing on the spinal CCS were also reviewed. We
retrospectively analyzed clinical data and outcome of all ten patients to present our understanding of spinal
CCS.
Results: Three en bloc and two piecemeal resections were performed successfully. The syndromes of all the
patients were obviously relieved after operation. The mean follow-up period was 24.4 months (range 10–41
months). Two patients died of lung metastasis 10 and 26 months after operation respectively. One patient was
alive with tumor recurrence. Other two patients were alive with no evidence of disease at last follow-up.
Conclusions: Prognosis of spinal CCS tend to be worse than CCS in common sites. En bloc resection could be
regarded as the ﬁrst treatment option. Tumor size, tumor location, preoperative neurological status and
resection mode might be the potential prognostic factors of spinal CCS.
1. Introduction
Clear cell sarcoma (CCS), a rare high-grade malignant tumor
accounting for less than 1% of all soft tissue sarcomas [1], was ﬁrst
described by Enzinger in 1965 [2]. In 1983, CCS was also named
malignant melanoma of the soft parts due to its histological similarities
to malignant melanoma, such as the presence of melanin, immunohis-
tochemical staining for melanoma-associated S-100 and HMB-45 [3].
With the discovery of chromosome translocation t(12;22) (q13;q12)
which leads to the generation of EWSR1-ATF1 fusion gene, clear cell
sarcoma was redeﬁned as a distinct type of tumor [4,5].
CCS is often located in the tendons or aponeuroses of the
extremities, especially in the foot and ankle [3,6–10]. However, CCS
in the spine is extremely rare and poorly understood. Only a few cases
speciﬁcally focusing on spinal CCS have been reported [11–15]. As a
high-grade malignant tumor, CCS is apt to recur and metastasize, with
a local recurrence rate of 84% and late metastasis rate of 63% [16].
Radical excision with negative margins is the best option for treating
CCS, but it is diﬃcult to achieve in the spine. Here, we retrospectively
analyzed clinical data from our patients along with a review of the
literature.
2. Materials and methods
A total of ﬁve patients with spinal CCS were diagnosed and treated
in our institution between October 2011 and December 2014. All the
ﬁnal pathological diagnoses were conﬁrmed by two independent
pathologists according to the following histopathological criteria: 1.
Tumors were microscopically characterized by a nested to fascicular
growth pattern of fusiform tumor cells and/or a diﬀuse sheetlike
fashion of much plumper polygonal or epithelioid cells. 2. In immu-
nohistochemical study, tumors were positivity for S-100, HMB45,
MITF, bcl-2, CD57, Melan A etc. 3. The chromosomal translocation
t(12;22) (q13;q12) or the resultant fusion gene EWSR1-ATF1 were
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detected by RT-PCR or FISH. [17].
We retrospectively reviewed the hospitalization records, progress
notes, surgery information, radiographic images and pathological
reports of all patients. This study was approved by the hospital ethics
committee and informed consent was obtained from all patients.
Of the ﬁve patients analyzed, one (case 4) had been subjected to an
incomplete tumor resection in other institution. She was admitted to
our center because of tumor recurrence. Other patients were regarded
as “intact” cases for they had not received any treatment before
admission.
X-ray, computerized tomography (CT) and magnetic resonance
imaging (MRI) of the spine were performed in all patients after
hospitalization. Tumors were further classiﬁed according to the
Enneking staging system for all patients and Weinstein-Boriani-
Biagini (WBB) classiﬁcation system for mobile spine based on radio-
graphic ﬁndings. Neurologic status was evaluated by Frankel scoring
system. One patient obtained her pathological diagnosis after operation
in other institution. Three patients received percutaneous needle
biopsy in our center. The remaining patient (case 5) refused to have
a needle biopsy for fear of possible nerve damage, though we
emphasized the signiﬁcance.
En bloc and piecemeal resections were performed in three and two
patients respectively. Patients were followed up at 3, 6, and 12 months
after surgery, every 6 months for the next 2 years, and anytime when
patients feel uncomfortable. X-ray and/or MRI examination were
performed at follow-up. The last status of patients was obtained from
oﬃce visit or telephone interview.
We also searched the articles related to the spinal CCS using
MEDLINE/PubMed as searching engine, and ﬁve case reports were
reviewed. Then we compared and analyzed both the data in the
literature and our own.
3. Results
3.1. Epidemiology and clinical presentation
Our series composed of three men and two women. The age of
patients ranged from 20 to 46 years at diagnosis, with a mean age of
27.8 years. The most common symptom was chronic pain, which often
radiated to the extremities and could not be relieved by aspirin or
acupuncture therapy. Tumor size ranged from 2.4 to 11.9 cm in the
maximum diameter, and three of ﬁve tumors were larger than 5 cm.
Tumor involved posterior elements in two cases, both vertebral body
and posterior elements in two cases, and sacrum in one case. Frankel
scores were as follows: one patient was Grade C; Grade D and E each
were documented in two patients. The clinical data of our patients are
listed in Table 1.
3.2. Radiologic studies
The plain radiographs of three patients showed bone destruction.
CT scan also demonstrated lytic lesions with irregular soft tissue
masses, and inhomogeneous enhancements could be seen after in-
travenous contrast enhancement. MRI is more sensitive for detecting
soft tissue lesions. The tumor lesion was mixed hyperintense on T1WI
and hypointense on T2WI, and inhomogeneous enhancement could
also be seen on MRI enhancement scan (Fig. 1).
3.3. Treatment
The whole operation process comprised tumor excision, decom-
pression of the spinal cord, reconstruction and stabilization of the
spine. Intraoperative frozen section examination was performed in all
ﬁve cases. Posterior approach was conducted in four patients, while the
other one (case 4) whose lesion involved cervical vertebra (zone 1–9 of
WBB system) used a combined anterior-posterior approach. En bloc Ta
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resection was performed on three cases (case 1, 2 and 3), other two
patients underwent a piecemeal resection. Postoperative pathology
examination conﬁrmed two negative margins (case 2 and 3) and one
contaminated margin (case 1) for en bloc-resected patients.
Intraoperative blood loss ranged from 400 to 6500 mL (mean
2320 mL). All patients recovered well without surgical complication
except one (case 4) suﬀered from cerebrospinal ﬂuid leakage which was
resolved by lumbar cistern drainage. Two patients (case 4 and 5)
received adjuvant radiotherapy, and chemotherapy was performed on
one (case 4) patient. In order to inhibit osteolysis, patients with tumor
> 5 cm (case 1, 4, and 5) also received bisphosphonate therapy.
3.4. Follow-up
The mean follow-up duration was 24.4 months (range 10–41
months). Pain and numbness were signiﬁcantly relieved in all patients
after operation. Two patients also experienced an improvement in
Frankel scores of 1–2 grades at their 3-month follow up visit. One
patient (case 1) experienced tumor recurrence 12 months after
operation. We advised him to have a second tumor resection but he
refused for economic reasons, and he was alive with tumor at last
telephone follow-up. Unfortunately, two patients (case 4 and 5) died of
lung metastasis 10 and 26 months after operation respectively.
Fig. 1. Images of a 46-year-old man (case 1). (A) The preoperative X-ray showed expansive bone destruction without osteosclerosis or periosteal reaction. (B and C) The preoperative
MRI revealed the tumor invaded sacrum and obstructed the spinal canal. The tumor was low signal intensity on T2-weighted image, and inhomogeneous enhancement could be seen on
MRI enhancement scan. (D and E) The preoperative CT scans (plain and enhancement) showed lytic lesion with large soft tissue mass and inhomogeneous enhancement. (F)
Hematoxylin and eosin (H&E) stain showed tumor cells were polygonal or spindle shaped with rich and transparent cytoplasm and arranged in fascicles and nests separated by ﬁbrous
septa. Nuclei were round to oval with predominant nucleoli. (G) Immunohistochemical study demonstrated positive cytoplasmic stainings for HMB-45. (H) The tumor was excised by an
en bloc method, pedicle screws, iliac screws and titanium rods were used to reconstruct the stability. Tumor recurrence was found by MRI in other institution 12 months after operation,
but the patient refused to provide his MRI ﬁlms. He rejected a second operation for economic reasons, and was alive with tumor at last telephone follow-up.
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4. Discussion
Clear cell sarcoma is a rare high-grade malignant sarcoma. It
typically aﬀects young adults in their third decades [3], with a mean
age ranging from 32 to 41 years [1,3,6,9] and an approximately equal
sex distribution [2,18,19]. The most common sites of CCS are
extremities. Chung et al. [3] reported 141 cases of CCS, 137 cases of
them occurred in extremities. However, CCS in the spine is extremely
rare and only a few cases have been described. We presented ﬁve cases
of spinal CCS in our institution, and also reviewed ﬁve cases from
literature [11–15] (listed on Table 2). Of all ten patients, the mean age
was 30.8 years, and female patients were almost equal to male patients,
which may demonstrate that patients with spinal CCS have similar
epidemiologic features as patients with CCS in common sites.
Spinal CCS, especially when tumor involves vertebra body or
sacrum, is not usually detected in early stage because of the nonspeciﬁc
clinical manifestations and deep location. As a result, the size of spinal
CCS in our series (median 5.3 cm, mean 6.3 cm) is larger than size of
CCS in common sites (median 3–4 cm) [1,6,18]. Initially, patients with
spinal CCS had no symptoms or felt only a slight back pain. They did
not take the slight pain seriously until symptoms became more and
more severe. Sometimes when patients sought treatment, the tumor
had already been too large to be resected completely. With the growth
of the tumor, some of them also complained of radiating pain and
neurologic deﬁcit due to spinal cord or root compression.
In order to facilitate surgery protocol formulation, we emphasize
the importance of needle biopsy. The radiological imaging of one
patient (case 4) hinted that the lesion was a benign neurogenic tumor,
and she refused to receive a preoperative biopsy for fear of possible
nerve damage. Unfortunately, the following incomplete resection of
such a malignant tumor in other hospital leaded to a poor prognosis.
Furthermore, melanocytes in CCS, perineural cells, and Schwann cells
share a common embryologic origin named neural crest cell [11],
which may explain why CCS is easily misdiagnosed as neurogenic
tumors. Immunohistochemistry is a good way to distinguish CCS
(positive for HMB-45) from neurogenic tumors (negative for HMB-
45) [16,20].
Radical surgical resection is the ideal treatment option for CCS.
Enzinger et al. [2] reported that patients who underwent a wide
resection or amputation had a mean survival of 10 years, while patients
who underwent a marginal or intralesional excision had an average
survival of 6 years. Hocar et al. [10] summarized that successful
treatment was accomplished by complete excision regardless of
whether there was an adjuvant therapy. Ferrari et al. [21] proposed
that if complete excision had been performed, adjuvant treatment
might have been unnecessary. Conversely, In the case of Zhang et al.
[11], tumor of the patient recurred nine months after surgery partly
because of the residual tumor causing by incomplete resection.
As for spinal CCS, Surgical removal of tumor is also the funda-
mental treatment strategy [11]. The Spinal operation aims to improve
or preserve neurological function, control local recurrence and prolong
the survival period [22,23]. En bloc, piecemeal and subtotal resections
are the surgical procedures applicable to spine [24]. In view of the
potential risk of tumor cell contamination in the surgical ﬁeld by
piecemeal resection, en bloc resection was regarded as the most ideal
method for treating spinal tumor. However, en bloc resection is hard to
achieve due to the anatomical complexity of spine area, especially when
the vital neurovascular structures are enclosed by tumors. In order to
achieve relatively good prognosis, three patients underwent an en bloc
resection, and we tried our best to remove the tumor as completely as
possible by a piecemeal method in other two patients. Only two
patients were alive with no evidence of disease at last follow-up, and
both of them received an en bloc resection with negative margins.
Therefore, facing such a high-grade malignant tumor, we advocate
adopting en bloc resection if situation allows. Admittedly, due to the
limited number of patients, our tentative idea needs to be proved by
further studies.
The eﬀectiveness of preoperative embolization has been conﬁrmed
to minimize intraoperative blood loss [25]. Although this intervention
may have no beneﬁt to the long-term prognosis of spinal CCS directly,
it may also have the potential of ischemic complications [26], yet
embolization can play a certain role in making surgery safer and easier.
We regretted not performing a preoperative embolization on case 5
who failed to have a more radical surgery partly because of profuse
bleeding (6500 mL). Thus we suggest that when tumor is compara-
tively large and with rich blood supply, preoperative embolization is
recommended.
The eﬀectiveness of radiotherapy on CCS is still in dispute. Kuiper
et al. [27] approved that adjuvant radiotherapy has a beneﬁcial eﬀect
on local control. While Ferrari et al. [21] insisted that radiotherapy was
of no beneﬁt for CCS. Meanwhile, the existence of both supporters
[7,21,28] and opponents [6,29] makes the role of chemotherapy in CCS
also remain controversial. In our series, patients who received adjuvant
radiotherapy or chemotherapy failed to achieve a good prognosis. Due
to the limited number of patients, we cannot draw the conclusion that
whether the adjuvant radiotherapy and chemotherapy are eﬀective in
spinal CCS. But considering the side eﬀects, radiotherapy and che-
motherapy should be applied cautiously.
Bisphosphonate has been demonstrated to have an inhibitory eﬀect
on proliferation and invasion of malignant bone tumors [30]. We used
bisphosphonate as an adjuvant treatment in patients with tumor >
5 cm. Novel therapies such as molecular targeted drug: Sunitinib [31],
and isolated limb perfusion [32] also has been used in CCS. These
therapeutic strategies oﬀer new sights for the treatment of CCS, but
further researches are needed.
In comparison with other high-grade malignant tumors, CCS has a
relatively good prognosis. 5-year survival ranges from 47–67% [6–
10,18], and 10-year survival rate drops to 25–41% [6,8–10,18].
However, in our series the mean follow-up period was 24.4 months,
only two of them were disease-free, which may indicate that the
prognosis of spinal CCS is worse than CCS in other sites. The reason
may be as follows: ﬁrstly, due to its deep site and the lack of clinical
manifestations in early time, spinal CCS is often diagnosed when the
tumor has already involved spinal cord or root and been too large to be
resected totally; furthermore, it is the anatomical complexity of spine
area that limits the application of radical surgery.
Comparing and analyzing the data of patients who were disease-free
(case 2 and 3) with patients who experienced tumor relapse or
Table 2
Clinical data of patients with spinal CCS reviewed from literature.
Author/year Age (y)/Sex Location Symptoms Resection Tumor size (cm) Adjunctive therapy Outcomes/Follow-up (month)
[11] 25/M Sacrum Pain and radicular pain Subtotal resection 11.0 – Local recurrence at 9 months
[12] 38/M T5−6 Pain and radicular pain NI 5.0 chemotherapy Local recurrence
[13] 41/M Sacrum Pain and numbness Total resection 3.0 – NED at 6 months
[14] 47/F C1−2 Altered sensation and Loss of function Total resection 2.0 – NI
[15] 18/F T4−5 Tingling, numbness and pain NI 6.0 – NI
M, male; F, female; NED, no evidence of disease; NI, no information.
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metastasis (case 1, 4 and 5), we found that tumor size, tumor location,
preoperative neurological status and resection mode could be the
potential prognostic factors of spinal CCS. Notably, large tumor size
( > 5 cm) has been reported as an independent adverse prognostic
factor by many studies [6,8,9]. In our case series and the case reviewed,
all of the patients suﬀered tumor recurrence or metastasis had a tumor
no less than 5 cm. Nevertheless, due to the limited number of patients
and follow-up time, it is diﬃcult for us to draw conclusions with
statistical signiﬁcance. And we are looking forward to larger and longer
researches for this challenging disease.
5. Conclusion
Spinal CCS is an extraordinarily rare tumor and hard to diagnose
with poor prognosis. En bloc resection, which is not always possible
due to the anatomical complexity of spine area and large tumor size, is
the ideal treatment option, while the role of adjuvant treatments is still
controversial. Vertebra body or sacrum involvement, large tumor size,
poor preoperative neurological status and non-radical resection might
be the potential negative prognostic factors of spinal CCS.
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